These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 15217988)
1. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Balani SK; Li P; Nguyen J; Cardoza K; Zeng H; Mu DX; Wu JT; Gan LS; Lee FW Drug Metab Dispos; 2004 Oct; 32(10):1092-5. PubMed ID: 15217988 [TBL] [Abstract][Full Text] [Related]
2. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Balani SK; Zhu T; Yang TJ; Liu Z; He B; Lee FW Drug Metab Dispos; 2002 Oct; 30(10):1059-62. PubMed ID: 12228180 [TBL] [Abstract][Full Text] [Related]
3. Metabolism of the cytochrome P450 mechanism-based inhibitor N-benzyl-1-aminobenzotriazole to products that covalently bind with protein in guinea pig liver and lung microsomes: comparative study with 1-aminobenzotriazole. Woodcroft KJ; Webb CD; Yao M; Weedon AC; Bend JR Chem Res Toxicol; 1997 May; 10(5):589-99. PubMed ID: 9168258 [TBL] [Abstract][Full Text] [Related]
4. In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice. Watanabe A; Mayumi K; Nishimura K; Osaki H Biopharm Drug Dispos; 2016 Sep; 37(6):373-8. PubMed ID: 27379984 [TBL] [Abstract][Full Text] [Related]
5. Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Linder CD; Renaud NA; Hutzler JM Drug Metab Dispos; 2009 Jan; 37(1):10-3. PubMed ID: 18936109 [TBL] [Abstract][Full Text] [Related]
6. Application of Osmotic Pumps for Sustained Release of 1-Aminobenzotriazole and Inhibition of Cytochrome P450 Enzymes in Mice: Model Comparison with the Hepatic P450 Reductase Null Mouse. Stringer RA; Ferreira S; Rose J; Ronseaux S Drug Metab Dispos; 2016 Aug; 44(8):1213-6. PubMed ID: 27271368 [TBL] [Abstract][Full Text] [Related]
7. N-aralkylated derivatives of 1-aminobenzotriazole are potent isozyme- and lung-selective mechanism-based inhibitors of guinea pig cytochrome P-450 in vivo. Knickle LC; Philpot RM; Bend JR J Pharmacol Exp Ther; 1994 Jul; 270(1):377-85. PubMed ID: 8035335 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of adrenal steroid metabolism by administration of 1-aminobenzotriazole to guinea pigs. Xu D; Voigt JM; Mico BA; Colby HD J Steroid Biochem Mol Biol; 1995 Sep; 54(5-6):281-5. PubMed ID: 7577711 [TBL] [Abstract][Full Text] [Related]
9. 1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. Sodhi JK; Ford KA; Mukadam S; Wong S; Hop CE; Khojasteh SC; Halladay JS Drug Metab Dispos; 2014 May; 42(5):813-7. PubMed ID: 24550229 [TBL] [Abstract][Full Text] [Related]
10. Antipyrine pharmacokinetics and urinary excretion in female horses. Dyke TM; Sams RA; Hinchcliff KW Am J Vet Res; 1998 Mar; 59(3):280-5. PubMed ID: 9522945 [TBL] [Abstract][Full Text] [Related]
11. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. Strelevitz TJ; Foti RS; Fisher MB J Pharm Sci; 2006 Jun; 95(6):1334-41. PubMed ID: 16625658 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
13. The effect of midazolam administration on the pharmacokinetics of antipyrine in the rat. White SM; Allen JG; Altman JF Xenobiotica; 1987 Jul; 17(7):869-73. PubMed ID: 3660856 [TBL] [Abstract][Full Text] [Related]
14. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Kharasch ED; Walker A; Hoffer C; Sheffels P Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460 [TBL] [Abstract][Full Text] [Related]
15. Utility of food pellets containing 1-aminobenzotriazole for longer term in vivo inhibition of cytochrome P450 in mice. Stringer R; Cordier V; Afatsawo C; Arabin P; Desrayaud S; Hoffmann L; Lehmann D; Lowe PJ; Risser F; Thiel J; Widmer T; Wipfli P; Bigaud M Xenobiotica; 2019 Jan; 49(1):13-21. PubMed ID: 29299977 [TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760 [TBL] [Abstract][Full Text] [Related]
18. In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). A tool for biochemical toxicology. Mico BA; Federowicz DA; Ripple MG; Kerns W Biochem Pharmacol; 1988 Jul; 37(13):2515-9. PubMed ID: 3390214 [TBL] [Abstract][Full Text] [Related]
19. Fluconazole is a potent inhibitor of antipyrine metabolism in vivo in mice. La Delfa I; Zhu QM; Mo Z; Blaschke TF Drug Metab Dispos; 1989; 17(1):49-53. PubMed ID: 2566469 [TBL] [Abstract][Full Text] [Related]
20. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]